Business
Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
BERKELEY HEIGHTS, N.J., March 17, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated,
About this update from Tonix Pharmaceuticals Holding Corp.
[{"type":"text","content":"BERKELEY HEIGHTS, N.J., March 17, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, today announced an oral presentation and two poster presentations on its preclinical immuno-oncology portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026, being held April 17–22, 2026, in San Diego, California. Oral Presentation Details Title: TFF2 deficiency amplifies IL-1β-driven inflammation and promotes aging-associated gastric tumor progressionAbstract #: 6822Date and Time: April 21, 2026, 2:30–4:30 p.m. PT (5:30-7:30 p.m. ET)Session Category: Tumor BiologySession Title: Aging Micro- and Macro-Environments in Tumor Progression and TherapyPresenters: Shuang Li, MD, PhD, and Timothy C. Wang, MD, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center (Tonix co-authors: Seth Lederman, MD, Chief Executive Officer, and Bruce L. Daugherty, PhD, MBA, Executive Vice President of Research) Poster Presentation Details Title: In vitro characterization of fully human antagonistic anti-BTLA monoclonal antibodiesPoster #: 6550Date and Time: April 21, 2026, 2:00-5:00 p.m. PT (5:00-8:00 p.m. ET)Session Category: Clinical ResearchSession Title: Immune Checkpoint BlockadeLocation: Poster Section 44, Board 16Presenter: Bruce Daugherty, PhD, MBA, Executive Vice President of Research, Tonix Title: Pharmacokinetics of TNX-1700 in non-human primates and human FcRn/serum albumin transgenic micePoster #: 7940Date and Time: April 22, 2026, 9:00 a.m.–12:00 p.m. PT (12:00-3:00 p.m. ET)Session Category: Clinical ResearchSession Title: Tumor Microenvironment Modulators Location: Poster Section 49, Board 15Presenter: Bruce Daugherty, PhD, MBA, Executive Vice President of Research, Tonix Copies of the Company’s presentations will be available under the Scientific Presentations tab on the Tonix website at www.tonixpharma.com. About TNX-1700TNX-1700, a fusion protein of TFF2 and albumin, is in preclinical development for the treatment of gastric and colorectal cancer in combination with PD-1 blockade. TNX-1700, in-licensed from Columbia University, is in the pre-Investigational New Drug (IND) stages of development. Tonix Pharmaceuticals Holding Corp.Tonix Pharmaceuticals* is a fully-integrated, commercial-stage bio...